Market Highlights
The Global
Myelodysplastic
Syndrome (MDS) drugs market is expected to grow significantly over the
forecast period. The Myelodysplastic Syndrome (MDS) drugs market held a valuation
of USD 1,581.59 million in 2018 and is projected to register a CAGR of 10.1%
over the forecast period.
The
increasing participation of key players is one of the key factors driving the Myelodysplastic
Syndrome (MDS) drugs market. In
2018, the US Food and Drug Administration approved generic injectable product
decitabine for Lupin Ltd. There are various other MDS medications available in
the market.
Various
other factors that are driving the MDS drugs market are the promotion of
clinical studies related to MDS, increasing geriatric population, rise in
regulatory approvals, and growing participation of generic drugs manufactures.
However,
the risk of infections during blood transfusions and side-effects of
chemotherapy may hamper market growth over the forecast period.
Segmentation
The global
Myelodysplastic Syndrome (MDS) drugs market is segmented based on product, type
of syndrome, route of administration, end user, and region.
Based on
product, the global Myelodysplastic Syndrome (MDS) drugs market is further
segmented into chemotherapy, immunomodulatory drugs, and others. The
chemotherapy segment is sub-segmented as conventional drugs and hypomethylating
drugs. Hypomethylating drugs include Azacitidine and Decitabine. Conventional
drugs comprise Cytarabine, Daunorubicin, and Idarubicin.
The MDS
drugs market at a global level is segmented on type of syndrome into refractory
cytopenia with multilineage dysplasia, refractory anemia, refractory anemia
with excess blasts, refractory anemia with ringed sideroblasts, refractory
cytopenia with multilineage dysplasia, and others.
Based on
the route of administration, the market is segmented into oral, parenteral, and
others. The MDS drugs available in the market are administered through
parenteral route, for instance, intravenous or subcutaneous. The parental route
has a quick effective after administration. Thus, the parenteral segments have
greater growth compared to the other dosage forms in this segment. Based on end
user, the market is segmented into hospitals, clinics, ambulatory surgical
centers, and others. MDS patients are treated in the
hospitals, clinics, and ambulatory surgical centers. MDS drugs are prescribed
by physicians to patients, as in critical conditions, it could lead to blood
cancer. The hospitals segment holds the major share in this segment as it deals
with a larger number of MDS patients compared to clinics and ambulatory
surgical centers.
Access Report
Details @ https://www.marketresearchfuture.com/reports/myelodysplastic-syndrome-drugs-market-8134
Key Players
Various
players operate in the global Myelodysplastic Syndrome (MDS) Drugs market such
as BluePoint Laboratories, Celgene Corporation, Celgene Europe Limited, Dr.
Reddy's Laboratories Inc., Johnson & Johnson, Lupin Ltd Corporation, Otsuka
America Pharmaceutical Inc, Sandoz, Shilpa Medicare Limited, Sun Pharmaceutical
Industries Inc, and others.
Regional
Analysis
In the
current scope of the study, the segments mentioned above are covered into the
four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle
East and Africa.
The global
MDS drugs market in the Americas has further been segmented into North America
and South America, with the North American market divided into the US and
Canada.
The
European global MDS drugs market has been segmented into Western Europe and
Eastern Europe. Western Europe has been classified as Germany, France, the UK,
Italy, Spain, and the rest of Western Europe. The MDS drugs market in
Asia-Pacific has been segmented into Japan, China, India, South Korea,
Australia, and the rest of Asia-Pacific. The global Myelodysplastic Syndrome
drugs market in the Middle East & Africa has been segmented into the Middle
East and Africa.
About Market Research Future:
At Market Research Future (MRFR), we enable our
customers to unravel the complexity of various industries through our Cooked
Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research
Reports (3R), Continuous-Feed Research (CFR), and Market Research &
Consulting Services.
MRFR team have supreme objective to provide the
optimum quality market research and intelligence services to our clients. Our
market research studies by Components, Application, Logistics and market
players for global, regional, and country level market segments, enable our
clients to see more, know more, and do more, which help to answer all their
most important questions.
In order to stay updated with technology and work
process of the industry, MRFR often plans & conducts meet with the industry
experts and industrial visits for its research analyst members.
Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: sales@marketresearchfuture.com
Blog: https://healthcarenews12.blogspot.com/
No comments:
Post a Comment